FDA looking at possible Singulair suicidality connection
The FDA issued an early communication advising that it is investigating a possible risk of suicidality with Merck's allergy and asthma drug Singulair.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.